Bacil Pharma FY26 net loss widens to ₹61.88 lakh
Bacil Pharma announced its audited financial results for FY26, reporting a net loss of ₹61.88 lakh compared to ₹6.17 lakh in the previous year. Revenue from operations fell to nil, with total revenue derived solely from other income of ₹123.52 lakh. Total expenses reduced to ₹24.50 lakh. For Q4 FY26, the net loss was ₹164.14 lakh, impacted by fair valuation losses on financial assets. Total assets rose to ₹2739.26 lakh, while cash and cash equivalents decreased to ₹56.85 lakh.
*this image is generated using AI for illustrative purposes only.
bacil pharma has reported a net loss of ₹61.88 lakh for the financial year ended March 31, 2026, a significant increase from the net loss of ₹6.17 lakh recorded in the previous fiscal year. The company's revenue from operations remained at nil for the year, compared to ₹198.50 lakh in the corresponding period of the previous year. Total revenue for the fiscal year was driven entirely by other income, which amounted to ₹123.52 lakh.
Financial Performance
Total expenses for the year decreased to ₹24.50 lakh, down from ₹204.68 lakh in the previous year, primarily due to the absence of purchases of stock in trade and material consumption costs. Other expenses were reported at ₹19.61 lakh, while employee benefits expense stood at ₹4.89 lakh. The Board of Directors approved the audited financial results at its meeting held on May 22, 2026.
Quarterly Breakdown
For the quarter ended March 31, 2026, the company reported a net loss of ₹164.14 lakh. This loss was largely impacted by a loss of ₹226.30 lakh recognized on the fair valuation of financial assets under Other Comprehensive Income (OCI). In the preceding quarter ended December 31, 2025, the company had posted a profit of ₹6.10 lakh.
Balance Sheet and Cash Flows
As of March 31, 2026, the company's total assets stood at ₹2739.26 lakh, a slight increase from ₹2560.02 lakh in the previous year. Investments constituted a major portion of non-current assets, valued at ₹2424 lakh. Cash and cash equivalents decreased significantly to ₹56.85 lakh from ₹285.73 lakh at the end of the previous year. The cash flow statement indicates a net decrease in cash and cash equivalents of ₹228.88 lakh during the year.
Key Financial Metrics
| Metric | Year Ended 31.03.2026 (₹ in Lakh) | Year Ended 31.03.2025 (₹ in Lakh) |
|---|---|---|
| Revenue from Operations | - | 198.50 |
| Other Income | 123.52 | - |
| Total Expenses | 24.50 | 204.68 |
| Profit/(Loss) for the Period | (61.88) | (6.17) |
| Basic EPS | 1.11 | (0.02) |
The statutory auditors, M/s. Sarang Shivajirao Chavan and Associates, have issued an unmodified opinion on the financial results.
Historical Stock Returns for Bacil Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.86% | -6.46% | -9.55% | +41.36% | +28.33% | +610.93% |
What is Bacil Pharma's strategic plan to resume revenue from operations, given that sales dropped to nil in FY2026 after ₹198.50 lakh in FY2025?
How will the continued depletion of cash reserves — down to ₹56.85 lakh from ₹285.73 lakh — impact Bacil Pharma's ability to fund operations and meet short-term obligations in FY2027?
What is the nature and performance outlook of the ₹2,424 lakh in investments that dominate the balance sheet, and could further fair valuation losses worsen the company's financial position?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
